U.S. Markets close in 7 mins

Aprea Therapeutics, Inc. (APRE)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
4.2600+0.0300 (+0.71%)
As of 3:53PM EDT. Market open.

Aprea Therapeutics, Inc.

535 Boylston Street
Boston, MA 02116
United States
617 463 9385

Full Time Employees11

Key Executives

NameTitlePayExercisedYear Born
Mr. Christian S. SchadePres, CEO & Chairman656.51kN/A1961
Mr. Scott M. CoianteSr. VP, Company Sec. & CFO320.79kN/A1967
Dr. Eyal C. Attar M.D.Sr. VP & Chief Medical Officer523.39kN/A1971
Dr. Lars B. AbrahmsenSr. VP & Chief Scientific OfficerN/AN/A1957
Dr. Gregory A. Korbel Ph.D.Sr. VP & Chief Bus. OfficerN/AN/A1976
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company's lead product candidate is APR-246 (Eprenetapopt), a small molecule p53 reactivator that is in late-stage clinical development for the treatment of hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia, as well as for relapsed/refractory TP53 mutant chronic lymphoid leukemia; and gastric, bladder, and non-small cell lung cancers. It also develops APR-548, a p53 reactivator that is on Phase I dose-escalation clinical trial for oral administration in MDS patients. The company was founded in 2006 and is headquartered in Boston, Massachusetts.

Corporate Governance

Aprea Therapeutics, Inc.’s ISS Governance QualityScore as of April 30, 2021 is 10. The pillar scores are Audit: 3; Board: 10; Shareholder Rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.